NASDAQ:TRIL - Trillium Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.30
  • Forecasted Upside: 10.09 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$18.44
+0.30 (1.20%)

This chart shows the closing price for TRIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trillium Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRIL

Analyst Price Target is $20.30
▲ +10.09% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Trillium Therapeutics in the last 3 months. The average price target is $20.30, with a high forecast of $25.00 and a low forecast of $18.50. The average price target represents a 10.09% upside from the last price of $18.44.

This chart shows the closing price for TRIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Trillium Therapeutics. This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2021BenchmarkDowngradeBuy ➝ HoldLow
10/1/2021Bloom BurtonInitiated CoverageBuy ➝ Hold$18.50Low
8/24/2021Craig HallumDowngradeBuy ➝ Hold$21.00 ➝ $18.50Low
8/24/2021JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/23/2021HC WainwrightDowngradeBuy ➝ NeutralC$22.00 ➝ C$18.50High
4/29/2021Bloom BurtonUpgradeAccumulate ➝ BuyMedium
4/26/2021JonestradingReiterated RatingBuy$25.00Medium
4/14/2021BenchmarkInitiated CoverageBuy$21.00Low
3/22/2021HC WainwrightReiterated RatingBuy$22.00Low
3/19/2021JonestradingReiterated RatingBuy$25.00Medium
12/8/2020Bloom BurtonDowngradeBuy ➝ AccumulateHigh
11/18/2020Craig HallumBoost Price Target$15.00 ➝ $21.00High
11/18/2020HC WainwrightBoost Price TargetBuy$16.50 ➝ $22.00High
10/12/2020Evercore ISIInitiated CoverageOutperform$28.00High
10/5/2020HC WainwrightReiterated RatingHoldHigh
9/10/2020HC WainwrightUpgradeNeutral ➝ Buy$16.50High
9/9/2020JMP SecuritiesBoost Price TargetPositive ➝ Market Outperform$10.00 ➝ $14.00High
8/17/2020Craig HallumInitiated CoverageBuy$15.00High
8/13/2020HC WainwrightReiterated RatingHoldHigh
5/26/2020JMP SecuritiesInitiated CoverageOutperform$10.00High
1/7/2020CowenReiterated RatingBuyMedium
11/18/2019HC WainwrightReiterated RatingHoldHigh
8/19/2019HC WainwrightDowngradeBuy ➝ NeutralLow
8/15/2019CowenReiterated RatingBuyMedium
5/17/2019HC WainwrightSet Price TargetBuy$4.00Low
3/13/2019HC WainwrightLower Price TargetBuy$10.00 ➝ $4.00High
12/20/2018CowenReiterated RatingBuyLow
11/15/2018HC WainwrightSet Price TargetBuy$10.00High
8/13/2018HC WainwrightReiterated RatingBuy$10.00Medium
4/17/2018HC WainwrightSet Price TargetBuy$10.00Low
4/13/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$7.00Low
3/12/2018HC WainwrightSet Price TargetBuy$10.00High
12/14/2017HC WainwrightReiterated RatingBuy$10.00High
8/14/2017HC WainwrightSet Price TargetBuy$7.00Medium
7/17/2017HC WainwrightInitiated CoverageBuy ➝ Buy$7.00High
7/5/2017CowenReiterated RatingBuyMedium
6/9/2017LADENBURG THALM/SH SHReiterated RatingBuy$18.00Low
12/5/2016CowenReiterated RatingBuyN/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/31/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/30/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Trillium Therapeutics logo
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $18.44
Low: $18.44
High: $18.44

50 Day Range

MA: $17.87
Low: $17.29
High: $18.44

52 Week Range

Now: $18.44
Low: $5.80
High: $20.96

Volume

8 shs

Average Volume

1,866,404 shs

Market Capitalization

$1.94 billion

P/E Ratio

29.74

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Trillium Therapeutics?

The following Wall Street research analysts have issued reports on Trillium Therapeutics in the last twelve months: Benchmark Co., Bloom Burton, Craig Hallum, HC Wainwright, JMP Securities, Jonestrading, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for TRIL.

What is the current price target for Trillium Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Trillium Therapeutics in the last year. Their average twelve-month price target is $20.30, suggesting a possible upside of 10.1%. Jonestrading has the highest price target set, predicting TRIL will reach $25.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $18.50 for Trillium Therapeutics in the next year.
View the latest price targets for TRIL.

What is the current consensus analyst rating for Trillium Therapeutics?

Trillium Therapeutics currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRIL, but not buy more shares or sell existing shares.
View the latest ratings for TRIL.

How do I contact Trillium Therapeutics' investor relations team?

Trillium Therapeutics' physical mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company's listed phone number is (416) 595-0627 and its investor relations email address is [email protected] The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.